AtlantiCare Regional Medical Center Becomes Fox Chase Cancer Center Partner
People with cancer in southeastern New Jersey will benefit immediately from a new cancer-focused affiliation recently announced by AtlantiCare Regional Medical Center (ARMC) and Fox Chase Cancer Center in Philadelphia, Pennsylvania. ARMC, southeastern New Jersey's newest home for outstanding cancer treatment, has been named a Fox Chase Cancer Center Partner, allowing ARMC to affiliate with one of the nation's leading cancer centers.
As a Fox Chase Partner, ARMC joins an elite network of 28 community hospitals in Pennsylvania, New Jersey and Delaware working cooperatively with Fox Chase Cancer Center to expand access to clinical trials and provide the most advanced options for cancer prevention, diagnosis and treatment. The Program will be known as AtlantiCare, The Cancer Care Institute, Fox Chase Cancer Center Partner to reflect its focus on cancer care and research. It will include the RNS Regional Cancer Center at ARMC.
"Through this affiliation we are expanding the scope and enhancing the quality of services we provide those living with cancer and their families," said James Wurzer, MD, PhD, medical director of Radiation Oncology at ARMC. "This partnership allows us to offer the community new programs for those at high risk of developing cancer, expanded cancer prevention studies and the most advanced cancer treatments."
"AtlantiCare doctors who serve those with cancer in southeastern New Jersey are committed to offering the most advanced treatment options," said Paul F. Engstrom, MD - Acting Director, Medical Oncology , senior vice president for extramural research programs at Fox Chase and medical director of Fox Chase Cancer Center Partners. "Equally important are the contributions AtlantiCare will make in advancing oncology medicine through expanding its participation in clinical studies. AtlantiCare has made a bold and important commitment to people of southeastern New Jersey - one that will directly impact their health."
Through its affiliation with Fox Chase, ARMC expands its participation in clinical studies, also called clinical trials. These trials include phase II and phase III (final testing stage) drug studies and other cancer treatment studies.
"Through our expanded clinical trials capabilities ARMC will contribute to new treatment technologies," said Louise Baca, RN, ARMC Clinical Trials coordinator. ARMC's expanded clinical trials participation will include chemoprevention trials aimed at reducing the risk of developing cancer. Chemoprevention is the use of natural or synthetic agents to prevent specific kinds of cancer.
The Fox Chase affiliation provides ARMC with access to its programs for people at higher than average risk of developing certain cancers because of family history or other factors. These programs, many of which will be available on-site at ARMC, provide counseling and information for those at increased risk of breast, ovarian, prostate and gastrointestinal cancers, and melanoma.
"When it comes to treating cancer, it takes a team of hundreds of people - backed by thousands of researchers," said David P. Tilton, president and CEO of ARMC. "The most important partner on our team is the patient. We're proud to welcome Fox Chase to our team in our quest to cure- and some day - prevent cancer."
Fox Chase offers AtlantiCare patients free access to cancer treatment guidelines, developed by physicians from 20 of the world's leading cancer centers, including Fox Chase, through its membership in the National Comprehensive Cancer Network (NCCN). These guidelines represent the most advanced treatment information available based on the latest cancer research. NCCN is a national alliance of 20 of the nation's leading cancer centers that work together to develop and institute standards, treatment guidelines and systems assuring high-quality, cost-effective cancer care. Fox Chase is a founding member of NCCN and is the only member in New Jersey, southeastern Pennsylvania and Delaware.
AtlantiCare Regional Medical Center (ARMC) is a two-campus, 567-bed hospital - ARMC City campus, Atlantic City, New Jersey and ARMC Mainland campus, Galloway, New Jersey. AtlantiCare, The Cancer Care Institute, Fox Chase Cancer Center Partner includes the Ruth Newman Shapiro Cancer Center at ARMC Mainland Campus. ARMC is part of AtlantiCare, the largest healthcare provider and one of the largest non-casino employers in southeastern New Jersey. For more information about ARMC's oncology programs and services, call the AtlantiCare Access Center at 1-888-569-1000.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Diana Quattrone at 215-728-7784.